Boxer Capital Management’s SAB Biotherapeutics SABS Stock Holding History
Bought
Maintained
Sold
Other funds holding SABS
Boxer Capital Management's SABS Position: Q3 2026 in Review
Boxer Capital Management opened a new position in SAB Biotherapeutics (SABS) in Q3 2026: 2,500,000 shares worth $7.92M. The stake represents 0.69% of the portfolio and ranks #23 among its holdings.
102 funds tracked by Wall St. Rank hold SABS as of Q3 2026.
- Boxer Capital Management held 2,500,000 shares of SAB Biotherapeutics worth $7.92M as of Q3 2026.
- SAB Biotherapeutics was a new Boxer Capital Management position in Q3 2026.
- SAB Biotherapeutics made up 0.69% of Boxer Capital Management's portfolio in Q3 2026, its #23 holding.
- 102 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2026.
Based on Boxer Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.